This multi-center, observational study will evaluate the use in clinical practice and efficacy of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the approved label will be followed for 6 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01615419?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
